Pharmacodynamic monitoring of immunosuppressive drugs

Clinical Chemistry

Volumn 44, Issue 2, 1998, Pages 428-432

  Yatscoff, Randall W ^a,b   Aspeslet, Launa J ^a   Gallant, Heather L ^b  

^a Isotechnika Inc   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN; CYCLOSPORIN; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THIOPURINE METHYLTRANSFERASE;

BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; ENZYME ACTIVITY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE; PHARMACODYNAMICS;

EID: 0031909930     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.2.428     Document Type: Conference Paper

References (22)

1. Oellerich M, Armstrong VW, Kahan BD, Shaw L, Holt DW, Yatscoff R, et al. Lake Louise consensus conference on cyclosporine monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995;17:642-54.
2. Sketris I, Yatscoff, Keown P, Canafax DM, First MR, Holt DW, et al. Optimizing the use of cyclosporine in renal transplantation. Clin Biochem 1995;28:195-211.
3. Pai SY, Fruman DA, Leong T, Neuberg D, Rosano TG, McGarigle C, et al. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood 1994;84:3974-9.
4. Batiuk TD, Pazderka F, Halloran PF. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation 1995;59:1400-4.
5. Mircheva J, Legendre C, Soria-Royer C, Thervet E, Beaune P, Kreis H. Monitoring of azathioprine-induced immunosuppression with thiopurine methyltransferase activity in kidney transplant recipients. Transplantation 1995;60:639-42.
6. Langman LJ, LeGatt DF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Clin Chem 1995;41:295-9.
7. Langman LJ, Shapiro AJ, Lakey RT, LeGatt DF, Kneteman NM, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model. Transplantation 1996;61:87-92.
8. Yatscoff RW, Gallant HL. P70 S6 kinase assay: a pharmacodynamic monitoring strategy for rapamycin; assay development. Transplant Proc 1996;6:3058-61.
9. Clipstone NA, Crabtree GR. Identification of calcinurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992;357: 695-7.
10. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136-42.
11. Weinshalboum RM, Slodek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
12. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992;53:1051-6.
13. Soria-Royer C, Legendre C, Mircheva J, Premel S, Beauve P, Kreis H. Thiopurine-methyltransferase activity to assess azathioprine myelotoxicity in renal transplant recipients. Lancet 1993;341: 1593-4.
14. Eugui EM, Mirkovich A, Allison A. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991;33:175-83.
15. Eugui EM, Almquist S, Mullen G, Allison A. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991;33:161-73.
16. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995;60:225-32.
17. Shaw LM, Sollinger H, Halloran PF, Morris RE, Yatscoff RW, Ransom J, et al. Mycophenolate mofetil: a report of the consensus panel. Ther Drug Monit 1995;17:690-9.
18. Murgia MG, Jordan S, Kahan BD. The side effect profile of Sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal-transplant patients. Kidney Int 1996;49:209-16.
19. Knight R, Ferraresso M, Serino F, Katz S, Lewis R, Kahan BD. Low-dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993;55:947-9.
20. Fryer J, Yatscoff RW, Pascoe EA, Thliveris J. Relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model. Transplantion 1993;55:340-5.
21. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signalling by the 70 kD S6 protein kinases. Cell 1992;69:1227-36.
22. Granger DK, Cromwell JW, Chen SC, Goswitz JJ, Morrow DT, Beierle FA, et al. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 1995;27:183.